EANO脑膜瘤诊断与管理指南
脑膜瘤是最常见的颅内肿瘤,但缺乏对照临床试验指导决策。欧洲神经肿瘤协会(EANO)更新指南,基于分子遗传学进展和临床试验结果,提出神经影像初步诊断、无症状或老年患者可观察等待、手术获取组织做WHO分类确诊、分子分型作用新兴、不可手术或复发者可放疗、全身治疗尚无标准方案。
要点
- 无症状或老年脑膜瘤患者可采用观察等待策略。
- 手术获取组织是WHO分类确诊的必需步骤。
- 不可手术或复发者可选放射外科或分次放疗。
核心结论
- 脑膜瘤诊断依赖神经影像初步判断,确诊需手术获取组织行WHO分类。
- 无症状或老年患者可观察等待,不可手术或复发者可选放射外科或分次放疗。
- 全身药物治疗尚无标准方案,贝伐珠单抗或多激酶抑制剂结果有限。
研究设计与样本
- 欧洲神经肿瘤协会(EANO)更新脑膜瘤诊断与治疗推荐。
主要发现
- 脑膜瘤是最常见颅内肿瘤,但仅有少数对照临床试验指导决策。
- 分子遗传学和临床试验进展有助于细化诊断和治疗策略。
- 分子分型包括基因面板测序和基因组甲基化分析作用新兴。
- 累及硬膜的全切手术常可治愈。
关键数值与推荐
- 无症状或老年患者可观察等待。
- 手术获取组织是WHO分类确诊所必需。
- 不可手术或复发肿瘤若大小或邻近关键结构允许,可选放射外科或分次放疗。
- 全身药物治疗尚无标准方案。
临床怎么用
- 神经影像初步诊断脑膜瘤后,无症状或老年患者可观察等待。
- 需确诊者应手术获取组织行WHO分类。
- 不可手术或复发者根据大小和邻近关键结构选择放射外科或分次放疗。
- 全身药物治疗尚无标准方案,贝伐珠单抗或多激酶抑制剂结果有限。
局限性
- 仅有少数对照临床试验指导临床决策。
- 放射治疗时机、类型和剂量仍存争议。
- 核素治疗和全身药物治疗均为实验性方法。
- 全身药物治疗尚无标准方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Meningiomas are the most common intracranial tumors. Yet, only few controlled clinical trials have been conducted to guide clinical decision making, resulting in variations of management approaches across countries and centers. However, recent advances in molecular genetics and clinical trial results help to refine the diagnostic and therapeutic approach to meningioma. Accordingly, the European Association of Neuro-Oncology (EANO) updated its recommendations for the diagnosis and treatment of meningiomas. A provisional diagnosis of meningioma is typically made by neuroimaging, mostly magnetic resonance imaging. Such provisional diagnoses may be made incidentally. Accordingly, a significant proportion of meningiomas, notably in patients that are asymptomatic or elderly or both, may be managed by a watch-and-scan strategy. A surgical intervention with tissue, commonly with the goal of gross total resection, is required for the definitive diagnosis according to the WHO classification. A role for molecular profiling including gene panel sequencing and genomic methylation profiling is emerging. A gross total surgical resection including the involved dura is often curative. Inoperable or recurrent tumors requiring treatment can be treated with radiosurgery, if the size or the vicinity of critical structures allows that, or with fractionated radiotherapy (RT). Treatment concepts combining surgery and radiosurgery or fractionated RT are increasingly used, although there remain controversies regard timing, type, and dosing of the various RT approaches. Radionuclide therapy targeting somatostatin receptors is an experimental approach, as are all approaches of systemic pharmacotherapy. The best albeit modest results with pharmacotherapy have been obtained with bevacizumab or multikinase inhibitors targeting vascular endothelial growth factor receptor, but no standard of care systemic treatment has been yet defined.
引用
- Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021. PMID: 34181733. doi:10.1093/neuonc/noab150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。